ロード中...
2119. Matched-Paired Analysis of Patients Treated for Invasive Mucormycosis—Standard Treatment vs. Posaconazole New Formulations (MoveOn)
BACKGROUND: Current first-line (first) antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B (AMB). Salvage (SAL) treatment options are limited and often based on posaconazole oral suspension (POSsusp). However, with the approval of posaconazole new formulations (P...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809098/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1799 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|